International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 1, January 2025 **ijppr.humanjournals.com** ISSN: 2349-7203

Sustainable and Green Injectable Formulations: Innovations, Challenges, and Future Perspectives in Pharmaceutical Development

Vidya UL*, Ramesh Kumar K, Dr.R.Devi Damayanthi, ArunKumar G, Meenakshi R, Mirunalini G

*Department of Pharmaceutics, College of Pharmacy, Madras Medical College, Chennai – 600 003 India.

Received: 2025-1-07 Revised: 2025-1-19 Accepted: 2025-1-25

ABSTRACT

Injectable medications play a crucial role in delivering drugs quickly and effectively, particularly in situations where fast action is needed or oral administration is not feasible. As the pharmaceutical industry evolves, there is a growing emphasis on creating more environmentally friendly injectable formulations. This review delves into the underlying principles, innovations, and challenges of developing sustainable injectables, focusing on the use of biodegradable ingredients, reducing waste, and applying green chemistry concepts. Several factors are driving this shift, including the need to reduce environmental impact, stricter regulatory requirements, and rising consumer demand for eco-conscious products. Sustainable methods in injectable drug development involve sourcing renewable raw materials, using safer solvents, and incorporating biocompatible excipients. In addition, adopting energy-efficient manufacturing techniques, water-based formulations, and eco-friendly packaging is vital for lowering the carbon footprint of injectable products. The review also highlights advancements such as biocatalysis in API production, the potential of nanotechnology, and sustainable biopharmaceutical processes, alongside strategies for better managing pharmaceutical waste. In conclusion, this review emphasizes how integrating sustainable practices can significantly improve the environmental footprint and overall effectiveness of injectable formulations.

Keywords: Sustainable Injectables, Green Chemistry, Biodegradable Excipients, Pharmaceutical Waste Management and Eco-friendly Formulations.

1. INTRODUCTION

Injectables are essential for administering drugs directly into the blood system, which lead fast and targeted pharmacological actions, especially for fast-acting disease management, or for drugs that cannot be taken orally. With the world steadily moving towards sustainability, even the pharmaceutical industry is required to develop formulations that are safe, effective and sustainable in nature. Green Chemistry principles, biodegradable excipients, minimization of waste, biocompatibility are basic aspects that contribute in making sustainable healthcare solutions. This review focuses on the principles, innovations, problems, and perspectives for the design of sustainable and green injectable formulations.

2. RATIONALE FOR DEVELOPMENT OF SUSTAINABLE AND GREEN INJECTABLES

2.1 Reduce Environmental Impact: The primary reason for opting for green injectable formulation is to reduce the environmental effect. Traditional pharmaceutical manufacturing processes routinely employ toxic chemicals, solvents and packaging materials that promote pollution and the depletion of resources.[1]

2.2 Increased Regulatory Pressure: The increasing pressure from governments and regulatory bodies across the globe, including pharmaceuticals, to transition to greener processes in the wake of climate change and environmental degradation. Many countries, for example, have adopted or are transitioning to stricter environmental regulations. Both the European Medicines Agency (EMA) and FDA are increasingly prioritizing sustainability. EMA has also developed scientific guideline on Environmental risk assessment of medicinal products for human use.[2]

2.3 Consumer Demand for Eco-Friendly Products: As environmental awareness grows among consumers, the demand for sustainable, eco-friendly pharmaceutical products is increasing. Patients, healthcare providers, and stakeholders are becoming more conscientious of how their treatment options impact the environment, and this is influencing purchasing and prescribing behaviour.[3]

2.4 Sustainability and Environmental Impact: Compared to conventional products, sustainable materials generally have a lower environmental footprint, supporting green practices. Conventional injections have deleterious effect on terrestrial wildlife and aquatic ecology. Injectable formulations involve direct delivery into the body, placing key importance on safety, biocompatibility, and low toxicity. The excipients, preservatives, and solvents employed in injectable formulations are often responsible for irritation, allergic reactions, or chronic toxicity in patients. Creating "green" materials which can be more environmentally friendly because they are biodegradable and derived from natural resources (lower toxicity, safer profile) are essential. The biocompatible and biodegradable excipients prevent accumulation of the formulation in the body, which further mitigates adverse effects. This is particularly critical in longer-term therapies, like biologics or vaccines, which require sustained engagement.[4]

3. PRINCIPLES OF SUSTAINABLE AND GREEN INJECTABLE FORMULATIONS

A sustainable and green formulation intends to limit environmental harm and resource use. Some principles behind their development are Reduction of harmful chemicals used, use of renewable raw materials, reduce environmental footprints, making the packaging system sustainable and regenerative and Biocompatible process.

ISO describes life cycle assessment (LCA) to quantitatively determine the impact on environment at all stages of product life cycle.[5]

This can help manufacture an injectable product that is sustainable as it reduces the use of lethal chemical agents including toxic solvents, excipients, preservatives that go into designs. The use of raw materials that can be obtained from renewable or biodegradable sources instead of petrochemical derivatives allows for the renewable use of raw materials. Diminishing wastage of water, energy, and material in production process reduces environmental impact. Minimize the plastic waste in injectable drug product with eco-friendly biodegradable or recyclable package. [6]

4. KEY COMPONENTS OF INJECTABLE FORMULATIONS

It primarily includes the active pharmaceutical ingredient (API) and the excipients (solvent, stabilizer, preservative, etc.) and the ultimate package or delivery system (for example vials and syringes) of the injectable formulations. There are several techniques with which these components may become sustainable.[7]

4.1 Active Pharmaceutical Ingredients (APIs): APIs are predominantly produced by synthetic chemical processes, which are typically environmentally unfriendly. Biocatalysis or sustainable synthetic routes included in green chemistry approaches attempt to minimize the environmental impact of such API production (Figure 1).[8] Pharmaceutical industries have also incorporated efforts to develop tools in order to maintain sustainable business practices. For instance, GSK (Glaxo Smith Kline) developed FLASC™ (fast life cycle assessment of synthetic chemistry) to implement sustainability in manufacture of APIs.[5]



Figure 1: Biocatalysis in API synthesis

4.2 Excipients: Conventional excipients may use deleterious chemicals, and their manufacturing procedures can create pollution. Novel excipients sourced from sustainable sources are being developed. Polysaccharides are among the materials that are widely studied, e.g., alginates, dextran and chitosan due to their biocompatibility and biodegradability. Also, Vitamin E derivatives are explored as stabilizers for protein-based injectable drugs.[9]

4.3 Solvents: Many solvents in conventional formulas, like Poly Ethylene Glycol, Propylene Glycol, are toxic to the environment and human health. Low Impact new, existing and alternative Technologies like Supercritical fluids (like CO_2) and water-based formulations are emerging as more sustainable alternatives. [10, 11]

4.4 Preservatives: Injectable formulations require preservatives like parabens, which are harmful to patients and the environment. Numerous preservatives are classified as chemicals of concern by various regulatory bodies. Research is concentrating on creating natural or less toxic preservatives that do not compromise the shelf life or efficacy of the product.[12]

5. METHODS TO ACHIEVE SUSTAINABILITY IN INJECTABLE FORMULATIONS

5.1 Green Chemistry in API Synthesis

It is easy to forget that green chemistry is one of the first principles in quality by design whose goal is to eliminate hazardous chemicals, solvents and energy in drug substance production. More sustainable approaches to API synthesis are being investigated including biocatalysis, solvent free reaction, renewable feedstock utilization, and waste reduction. [13-15]

Biocatalysis use soluble or immobilized whole cell microbe and isolated enzymes or its mutant as a catalyst to promote the production of API with less toxic reagents. Biocatalysis is more selective, efficient and environmentally beneficial in contrast with traditional chemical reactions. For example, usage of enzymes to synthesize chiral molecules (e.g., optically pure drugs) that are difficult to produce using conventional synthetic chemistry. [16, 17]

Another approach for sustainable API synthesis is reactions in the absence of solvents or solid-state synthesis, reduce usage of solvents which direct waste of solvents and energy consumption. For example: A mechanochemistry (Figure 2) where reactions start to perform without solvents meets to synthesize APIs.[18]



Figure 2: Mechanochemistry in API Production

APIs are also being derived from renewable resources as opposed to petrochemical byproducts, with plant-based or bio-based materials being used increasingly. Example: Plant-based compounds (e.g., cannabinoids or natural antibiotics like penicillin) are being extracted from renewable resources and refined into injectable formulations.[19]

More sustainable protocols such as atom economy (where most of the reagents end up in the desired product), catalysis (that requires less reagents), all of them reduces chemical waste and consequently the environmental footprint.[20]

5.2 Biodegradable and Eco-Friendly Excipients

Excipients are crucial in injectable formulations to stabilize the drug, enhance solubility, or control release. Green and biodegradable excipients are emerging as alternatives to traditional chemical-based excipients they include;

Polysaccharides: They are biodegradable, nontoxic, and biocompatible, natural polymers which include alginate, chitosan, and dextran. These polysaccharides are suitable excipients in injectable drug delivery systems that minimize the environmental impact and promote patient safety. Example: Alginate is used in formulations for controlled release of drug and vaccines, where it is broken down naturally in the body.[21]

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 1, January 2025 ijppr.humanjournals.com ISSN: 2349-7203

Lipid-based Carriers: Liposomal formulations are biodegradable carriers composed of naturally derived lipids that can encapsulate the drug and improve its bioavailability. Once inside the body, these formulations break down into harmless components such as fatty acids. Example: Liposomes made from phospholipids (which are naturally occurring) are used in various injectable formulations, offering both sustainability and biocompatibility. [22, 23]

Polylactic Acid (PLA) and Poly(lactic-co-glycolic acid) (PLGA): PLGA biopolymers, as a biodegradable polymer with high applicability in controlled-release drug delivery systems, such as injectable formulations. Later they are metabolized into lactic acid or glycolic acid, which are naturally found in the body. [24, 25]

5.3 Water-Based Formulations

Compared to organic solvents, such as ethanol or propylene glycol, water is more eco-friendly and has lower environmental and toxicological footprint. Development is moving toward more water-based formulations, which greatly enhances the sustainability of injectable drugs.

Water-soluble or dispersible drugs and excipients can eliminate potentially toxic or non-renewable solvents during manufacture. Example: Water-based solutions of biologics or vaccines can be injected without the use of harmful solvents or preservatives.

Use of Supercritical Fluids (e.g., Supercritical CO_2), Supercritical CO_2 is a green solvent for the extraction and formulation of injectable drugs (Figure 3). It is not harmful, and when used avoids organic solvents, thus lowering waste and enhancing the eco-friendliness of the manufacturing process.[10]



Figure 3: Supercritical Fluid (CO_2) based formulation

5.4 Green Packaging

Packaging represents a key part of the environmental footprint of injectable products. Sustainable packaging methods intend to mitigate plastic waste and promote recyclability. [26, 27]

Bioplastic, for example PLA (polylactic acid) or biodegradable polymers sourced from renewable resources can help alleviate waste build-up. For example, plant-based packaging of syringes or vials that degrades easily after use.[28]

One way to minimize waste is by packaging with as little as possible. Also, to reduce single-use packaging (Minimalist Packaging), research is underway into bulk packaging or refillable options (Figure 4). Example: refillable syringes or bulk drug delivery systems that can help limit the need for repeated single doses.[29]

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 1, January 2025 ijppr.humanjournals.com ISSN: 2349-7203



Figure 4: Refillable Syringes

Recyclable Containers: The materials used for packaging are recyclable such as glass or metal, promoting less use of single-use plastics. Example: Glass vials instead of plastic vials for injectable drugs.

5.5 Green Manufacturing Processes

Making injectable formulations takes a lot of energy and raw materials, but this footprint can be minimized by giving sustainability considerations.

Sustainability is about manufacturing processes that use low energy (Energy-Efficient Manufacturing) and produce low waste. This may involve optimizing production processes with, energy-efficient equipment, and renewable energy sources. For instance, solar energy, wind energy, etc. in designing production facilities to lower reliance on fossil fuels. [30, 31]

Rather than batch production, continuous manufacturing uses automated processes that run 24/7, potentially cutting waste and increasing energy efficiency. It can reduce the carbon footprint as compared to conventional batch manufacturing (Figure 5).[32]



Figure 5: Batch manufacturing vs Continuous manufacturing

5.6 Nanotechnology for Sustainable Injectable Formulations

Nanotechnology provides several opportunities to enhance the sustainability and efficacy of injectable formulations.[33]

Biodegradable polymeric or lipid-based nanoparticles allow for controlled release and targeted drug delivery, enhancing therapeutic efficacy, while being less toxic to the environment. Example: Polymeric nanoparticles that encapsulate drugs and release them gradually, reducing the need for frequent injections.[34]

Nanomaterials like graphene or carbon nanotubes could be used to improve the bioavailability of the drug and to minimize the material required for effective therapy.[35]

5.7 Sustainable Biopharmaceutical Production

Biopharmaceuticals, and especially biologic drugs (monoclonal antibodies or gene therapies), need dedicated, sustainable production pathways.[36]

Many plant culture methods are beginning to slow reliance on animals or minimize environmental impact through plant use and an indirect preference for microbes over mammalian cell development for production systems. Plant-based biomanufacturing systems, e.g., for manufacture of vaccines or therapeutic proteins. [37, 38]

Better utilization can be achieved by bioreactor optimization, rich yield and process intensification reduce the waste generated and consequently, the resource consumption.[39]

5.8 Pharmaceutical Waste Management

Waste management is important for minimizing the environmental burden of injectable formulations. Using zero-waste principles to manufacture the products, any excess raw material or chemical by-products are reused and recycled rather than being polluted. For Example: Waste minimization, By-products of the production process are often used in other sectors, thus reducing waste.[40]

Working on developing a biodegradable syringe of some sort, or an eco-friendly disposal system for disposable injectables ensures that ubiquitous part of our medical waste from injectables would no longer contribute to ultimate landfill trouble or toxicity pollution.[41]

6. CONCLUSION:

The transition towards sustainable and green injectable formulations is a crucial development for minimizing the ecological impact of the pharmaceutical industry. By adopting green chemistry principles, using biodegradable excipients, and implementing water-based formulations and eco-friendly manufacturing practices, the industry can significantly reduce its environmental footprint while preserving the efficacy and safety of injectable drugs. The ongoing research in sustainable excipients, innovative methods for API synthesis, and alternative packaging is paving the way for a more environmentally responsible approach to drug delivery. Moreover, breakthroughs in biopharmaceutical production, nanotechnology, and waste management offer new opportunities to further reduce the industry's environmental burden. As regulatory pressures and consumer demand for environmentally conscious products grow, the integration of sustainability in injectable drug development is becoming increasingly vital. With continued advancements and collaboration, the future of injectable formulations promises to be both sustainable and effective, representing a significant step forward in the healthcare industry's commitment to environmental responsibility.

REFERENCES:

1. Riikonen S, Timonen J, Sikanen T. Environmental considerations along the life cycle of pharmaceuticals: Interview study on views regarding environmental challenges, concerns, strategies, and prospects within the pharmaceutical industry. Eur J Pharm Sci. 2024;196:106743.
2. Küster A, Adler N. Pharmaceuticals in the environment: scientific evidence of risks and its regulation. Philos Trans R Soc Lond B Biol Sci. 2014 Nov 19;369(1656):20130587.
3. Camilleri MA, Cricelli L, Mauriello R, Strazzullo S. Consumer perceptions of sustainable products: A systematic literature review. Sustainability. 2023;15(11):8923.
4. Ashiwaju B, Uzougbo C, Orikpete O. Environmental impact of pharmaceuticals: A comprehensive review. Matrix Sci Pharma. 2024;7:85-94.
5. Becker J, Manske C, Randl S. Green chemistry and sustainability metrics in the pharmaceutical manufacturing sector. Curr Opin Green Sustain Chem. 2022;33:100562.
6. Valavanidis A, Vlachogianni T. Laboratory experiments of organic synthesis and decomposition of hazardous environmental chemicals following green chemistry principles. Sci Adv. 2011;1:1-12.

7. Pramanick S, Sinodia D, Chandel V. Excipient selection in parenteral formulation development. Pharma Times. 2013;45(3):65-75.
8. Ahmad S, Jaiswal R, Yadav R, Verma S. Recent advances in green chemistry approaches for pharmaceutical synthesis. Sustain Chem One World. 2024;4:100029.
9. Katdare, A., & Chaubal, M. (Eds.). (2006). Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems (1st ed.). CRC Press.
10. Liu H, Liang X, Peng Y, Liu G, Cheng H. Supercritical fluids: An innovative strategy for drug development. Bioengineering. 2024;11(8):788.
11. López-Iglesias C, Quílez C, Barros J, Velasco D, Alvarez-Lorenzo C, Jorcano JL, Monteiro FJ, García-González CA. Lidocaine-loaded solid lipid microparticles (SLMPs) produced from gas-saturated solutions for wound applications. Pharmaceutics. 2020;12(870)
12. Allwood MC. Antimicrobial agents in single- and multi-dose injections. J Appl Bacteriol. 1978;44:Svii-Sxvii.
13. Valavanidis A, Vlachogianni T. Laboratory experiments of organic synthesis and decomposition of hazardous environmental chemicals following green chemistry principles. Sci Adv. 2011;1:1-12.
14. Al-Awamleh H, Alhalalmeh M, Alatyat Z, Saraireh S, Akour I, Alneimat S, Al-Hawary S. The effect of green supply chain on sustainability: Evidence from the pharmaceutical industry. Uncertain Supply Chain Manag. 2022;10(4):1261-1270.
15. Kurteva VB, Santos AG, Afonso CAM. Microwave accelerated facile synthesis of fused polynuclear hydrocarbons in dry media by intramolecular Friedel-Crafts alkylation. Org Biomol Chem. 2004;2:514-523.
16. Lewis RD, France SP, Martinez CA. Emerging technologies for biocatalysis in the pharmaceutical industry. ACS Catal. 2023;13(8):5571-5577.
17. Adams JP, Brown MJB, Diaz-Rodriguez A, Lloyd RC, Roiban GD. Biocatalysis: A pharma perspective. Adv Synth Catal. 2019;361(11):2421-2432.
18. Emília P. T. Leitão. Comparison of traditional and mechanochemical production processes for nine active pharmaceutical ingredients (APIs). RSC Sustain. 2024;2(12):3655-3668.
19. Angelini P. Plant-Derived Antimicrobials and Their Crucial Role in Combating Antimicrobial Resistance. Antibiotics. 2024; 13(8):746.
20. Sheldon RA, Bode ML, Akakios SG. Metrics of green chemistry: Waste minimization. Curr Opin Green Sustain Chem. 2022;33:100569.
21. Cadinoiu AN, Rata DM, Atanase LI. Biocompatible injectable polysaccharide materials for drug delivery. Woodhead Publishing; 2019:127-154.
22. Mall J, Naseem N, Haider MF, Rahman MA, Khan S, Siddiqui SN. Nanostructured lipid carriers as a drug delivery system: A comprehensive review with therapeutic applications. Int Pharm. 2024.
23. Molska A, Nyman AKG, Sofias AM, Kristiansen KA, Hak S, Widerøe M. In vitro and in vivo evaluation of organic solvent-free injectable melatonin nanoformulations. Eur J Pharm Biopharm. 2020;152:248-256.
24. Tyler B, Gullotti D, Mangraviti A, Utsuki T, Brem H. Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Adv Drug Deliv Rev. 2016;107:163-175.
25. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377-1397.
26. Gold K. Analysis: The impact of needle, syringe, and lancet disposal on the community. J Diabetes Sci Technol. 2011;5(4):848-850.
27. Boehringer Ingelheim. NeO - Smart and sustainable vaccines [Internet]. 2020 [cited 2020 Dec 20]. Available from: https://www.boehringer-ingelheim.com/animal-health/our-responsibility/neo-smart-and-sustainable-vaccines
28. Ashiwaju B, Orikpete O, Fawole A, Alade E, Odogwu C. A step toward sustainability: A review of biodegradable packaging in the pharmaceutical industry. Matrix Sci Pharma. 2024;7:73-84.
29. Pfizer. Product packaging [Internet]. 2020 [cited 2024 Dec 14]. Available from: https://www.pfizer.com/purpose/workplace-responsibility/green-journey/packaging
30. Moussaoui H. Achieving energy savings and process optimization in plastic injection molding: A design of experiments study. J Clean Prod. 2024;477:143835.
31. Spiering T, Kohlitz S, Sundmaeker H, Herrmann C. Energy efficiency benchmarking for injection moulding processes. Robotics Comput Integr Manuf. 2015;36:45-59.
32. Yamada M, Badr S, Udugama IA, Fukuda S, Nakaya M, Yoshioka Y, Sugiyama H. A systematic techno-economic approach to decide between continuous and batch operation modes for injectable manufacturing. Int J Pharm. 2022;613:121353.
33. Naiel B, Fawzy M, Halmy MW, et al. Green synthesis of zinc oxide nanoparticles using Sea Lavender (Limonium pruinosum L. Chaz.) extract: characterization, evaluation of anti-skin cancer, antimicrobial and antioxidant potentials. Sci Rep. 2022;12:20370.
34. Su S, Kang PM. Systemic review of biodegradable nanomaterials in nanomedicine. Nanomaterials. 2020;10(4):656.
35. Costa HPS, Duarte EDV, da Silva FV, da Silva MGC, Vieira MGA. Green synthesis of carbon nanotubes functionalized with iron nanoparticles and coffee husk biomass for efficient removal of losartan and diclofenac: Adsorption kinetics and ANN modeling studies. Environ Res. 2024;251(Part 2).

36. Partopour B, Pollard D. Advancing biopharmaceutical manufacturing: economic and sustainability assessment of end-to-end continuous production of monoclonal antibodies. Trends Biotechnol. 2024 Nov 6;S0167-7799(24)00289-0.
37. Kumar M, Kumari N, Thakur N, Bhatia SK, Saratale GD, Ghodake G, Mistry BM, Alavilli H, Kishor DS, Du X, Chung SM. A comprehensive overview on the production of vaccines in plant-based expression systems and the scope of plant biotechnology to combat against SARS-CoV-2 virus pandemics. Plants (Basel). 2021;10(6):1213.
38. Eidenberger L, Kogelmann B, Steinkellner H. Plant-based biopharmaceutical engineering. Nat Rev Bioeng. 2023;1:426-439.
39. Uniyal S, Bijalwan PK. Scaling up bioreactor systems for sustainable biorefinery: A crucial step in advancing the green economy. In: Agrawal K, Verma P, editors. Biotechnological advances in biorefinery. Interdisciplinary Biotechnological Advances. 2024: 231-248.
40. Ahmed SF, Kabir M, Mehjabin A, Oishi FTZ, Ahmed S, Mannan S, Mofijur M, Almomani F, Badruddin IA, Kamangar S. Waste biorefinery to produce renewable energy: Bioconversion process and circular bioeconomy. Energy Rep. 2023;10:3073-3091.
41. Phadke R, Dos Santos Costa AC, Dapke K, Ghosh S, Ahmad S, Tsagkaris C, Raiya S, Maheswari MS, Essar MY, Ahmad S. Eco-friendly vaccination: Tackling an unforeseen adverse effect. J Clim Change Health. 2021;1:100005.

How to cite this article:
Vidya UL et al. Ijppr.Human, 2025; Vol. 31 (1): 160-167.
Conflict of Interest Statement: All authors have nothing else to disclose.